Vaccines Market

Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) (2022 - 2026)

Report Code: PH 6528 Jan, 2022, by marketsandmarkets.com

[302 Pages Report] The global vaccines market is projected to reach USD 67.2 billion by 2026, at a CAGR of 10.2%. The global vaccines market (including COVID-19 vaccines) is projected to reach USD 149.2 billion by 2026 during the forecast period. The advent of infectious diseases and re-emerging diseases due to overuse of antibiotics, etc. is driving the market growth. Furthermore, rising healthcare awareness and a number of government organizations undertaking initiatives to focus on immunization is also boosting the global vaccines market growth.

Vaccines Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the Vaccines Market

The outbreak of the COVID-19 pandemic changed the market dynamics for the vaccines market. In 2020, there was a slight decrease in the traditional vaccine market since the focus shifted from common vaccines to COVID-19 vaccines. According to the UNICEF COVID-19 Vaccine Market Dashboard, 28 COVID-19 vaccines have been approved for use by at least one national regulatory authority worldwide. Out of them, 8 vaccines have found their place in WHO’s Emergency Use Listing (EUL). Overall, 21.1 billion doses of different COVID-19 vaccines have been secured globally (as of December 6, 2021).

Global Vaccines Market Dynamics

DRIVER: Increasing focus on immunization programs

The focus on immunization has increased considerably with rising healthcare awareness, and a number of government organizations are undertaking initiatives to meet this goal. The Australian government’s Immunise Australia Program, for example, provides funds for the purchase of vaccines. The program also implements the National Immunization Programme (NIP) Schedule, which currently includes vaccines for 16 diseases, including measles, diphtheria, and whooping cough (pertussis), as well as the more recently developed vaccines, such as the HPV and meningococcal ACWY vaccine. This schedule is mandatory for every Australian from birth. Such factors are driving the market growth.

RESTRAINTS: Low purchasing power in developing countries

The traditional six vaccines in the Expanded Programme on Immunization (EPI)—measles, diphtheria, pertussis, tetanus, oral polio, and BCG—are mature products. High fixed costs and a steep learning curve make new vaccines relatively more expensive, as the investments in R&D and production facilities need to be paid off, and optimum production techniques need to be perfected to bring down variable production costs. New vaccines that involve recombinant DNA technology or conjugation of a polysaccharide with a protein may not be as amenable to large-scale production as vaccines produced by more traditional techniques. Therefore, the prices for these vaccines may never reach the same low level as the traditional six EPI vaccines. Consumers used to purchasing the traditional six EPI vaccines at low prices may be unwilling to pay the high price demanded for innovative new products, especially where financial constraints are tight.

OPPORTUNITY: Focus on therapeutic vaccines

Therapeutic vaccines enable corrective treatment, as opposed to preventive vaccines. An improved understanding of immunology has resulted in the opportunity to develop these therapeutic vaccines for the treatment of cancer, allergies, physiological disorders, and infectious diseases. Such diseases have a large patient base that desperately seeks alternative treatments. Scientists have attempted to develop novel therapeutic vaccines against hypertension, dyslipidemia, Alzheimer’s disease, cancer, and inflammatory diseases by targeting self-antigens. If the efficacy and safety of vaccines can achieve an effect equivalent to that of medication, vaccines may be an alternative to daily medication for the treatment of lifestyle diseases.

CHALLENGES: Vaccine misinformation

Misinformation often arises when there are information gaps or unsettled science, as human nature seeks to reason, better understand, and fill in the gaps. In the first 3 months of 2020, nearly 6,000 people around the globe were hospitalized because of coronavirus misinformation, recent research suggests. During this period, researchers say at least 800 people may have died due to misinformation related to COVID-19. Vaccine disinformation and misinformation are a major concern among governments, funding agencies, vaccine manufacturers and suppliers, and other stakeholders alike. Low acceptance rates due to vaccine misinformation result in the lower market penetration of effective and safe vaccines, which could adversely affect the market.

Conjugate vaccines segment accounted for the largest share of the technology segment (excluding COVID 19 vaccines)

Based on technology, the conjugate vaccines segment dominated the market with maximumt share of the global vaccines market (excluding COVID-19 vaccines), in 2020. Conjugate vaccines are prepared by linking antigens or toxoids from a microbe so that the immune system of individuals can recognize the polysaccharides of bacteria. This linkage helps the immune system of infants and young children react to the polysaccharides and develop immunity against the bacterium. Such benefits of these vaccines are contributing to the large segment share.

The HPV vaccines market to grow at the highest rate during the forecast period in 2020

In 2020, the HPV disease segment accounted for the highest CAGR of the vaccines market, by disease indication. The growing prevalence of diseases caused by the HPV family of viruses is driving attention to the provision and use of better, more effective vaccines. In 2020, 604,127 cervical cancer cases were recorded globally. In the same year, global mortality increased to over 340,000 women. Due to population growth, both numbers are likely to continue to increase, particularly in underprivileged and vulnerable communities.

Multivalent vaccines segment is expected to grow at a highest CAGR of the type segment

In 2020, the multivalent vaccines segment is expected to grow at a highest CAGR of the global vaccines market (excluding COVID-19 vaccines). Growing companies’ investment in R&D activities for gaining regulatory approvals that ensure the safety and efficacy of the vaccines coupled with increasing initiatives by manufacturers to develop new multivalent vaccines are driving the growth of this segment.

Pediatric vaccines segment accounted for the largest share of the end user segment

On the basis of end user, the pediatric users segment comprised for the maximum share of the vaccines market (excluding COVID 19 vaccines). This segment growth can be attributed to the fact that vaccinations tend to be more effective in children since their immune systems respond better to vaccines and help them gain lifelong immunity against specific diseases. Children are also more susceptible to various infectious diseases, such as tuberculosis, measles, hepatitis, and cholera, which highlight the need for effective pediatric vaccination.

Oral route of administration segment accounted for the second largest share of the route of administration segment

In 2020, the oral route of administration segment accounted for second largest share of the vaccines market (excluding COVID-19 vaccines). The oral route is the simplest, most convenient, and safest route of administration and offers significant advantages compared to the parenteral delivery of vaccines in terms of cost, safety, and patient acceptability. In addition, the oral route of vaccination provides both social and economic advantages, especially in developing countries.

Vaccines Market  by Region

To know about the assumptions considered for the study, download the pdf brochure

Asia Pacific to grow at the highest CAGR in the regional Vaccines market in 2020.

The vaccines market in the Asia Pacific is expected to register the highest CAGR (including COVID-19 vaccines) and (excluding COVID-19 vaccines) during the forecast period. Growing number of drug and vaccine manufacturers are outsourcing large parts of R&D mostly to clinical/contract research and manufacturing organizations with the aim to reduce costs. This is a major factor supporting the growth of the vaccines market in the Asia Pacific.

Key Market Players

Key players operating in the global vaccines market include GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Sanofi SA (France), and Pfizer, Inc. (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Technology, Type, Disease Indication, Route of Administration, End User, Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Companies covered

GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca plc (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic A/S (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec, Ltd. (India), Biological E Limited (India), Bharat Biotech Ltd. (India), Novavax, Inc. (US), FSUE NPO Microgen (Russia), Sinovac Biotech, Ltd. (China), Incepta Vaccine Limited (Bangladesh), Valneva SE (France), VBI Vaccines (US), PT Bio Farma (Persero) (Indonesia), Inovio Pharmaceuticals, Inc. (US), Chongqing Zhifei Biological Products Co., Ltd. (China), and Indian Immunologicals Limited (India).

This report categorizes the vaccines market into the following segments and subsegments:

Vaccines Market, by Technology (excluding COVID 19 vaccines)

  • Conjugate vaccines
  • Inactivated & Subunit vaccines
  • Live Attenuated vaccines
  • Recombinant vaccines
  • Toxoid vaccines
  • Viral vector vaccines

COVID 19 Vaccines Market, by Technology

  • mRNA vaccines
  • Viral Vector vaccines
  • Other vaccines (inactivated, recombinant, conjugate, subunit, peptide, and DNA vaccines)

Vaccines Market, by Type

  • Monovalent vaccines
  • Multivalent vaccines

Vaccines Market, by Disease Indication

  • Influenza
  • Pneumococcal diseases
  • Combination vaccines
  • HPV
  • Herpes Zoster
  • Meningococcal diseases
  • Rotavirus
  • MMR
  • Varicella
  • Hepatitis
  • DTP
  • Polio
  • COVID 19
  • Other disease indications (cancer, dengue, tuberculosis, typhoid, Japanese encephalitis, rabies, yellow fever, and allergies)

Vaccines Market, by Route of Administration

  • Intramuscular & Subcutaneous administration
  • Oral administration
  • Other routes of administration (intranasal, intradermal, and percutaneous)

Vaccines Market, by End-user (excluding COVID 19 vaccines)

  • Pediatric vaccines
  • Adult vaccines

Vaccines Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • China
    • India
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Rest of Latin America (RoLA)
    • Middle East & Africa

Recent Developments

  • In October 2021, Pfizer received the US FDA Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age.
  • In August 2021, Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full US FDA approval for individuals 16 years and older.
  • In July 2021, GSK received US FDA approval for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy.
  • In June 2021, Merck announced the launch of VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) in the US, developed in partnership with Sanofi Pasteur.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 38)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
                    TABLE 1 VACCINES MARKET: INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 VACCINES MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 44)
    2.1 RESEARCH DATA
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF PRIMARIES: VACCINES MARKET
    2.2 MARKET ESTIMATION METHODOLOGY
           FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS
           FIGURE 6 CAGR PROJECTIONS (SUPPLY-SIDE): VACCINES MARKET (EXCLUDING COVID-19 VACCINES)
           FIGURE 7 VACCINES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
    2.4 DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS
    2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 54)
    FIGURE 9 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 
    FIGURE 10 COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 
    FIGURE 11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2021 VS. 2026 (USD MILLION)     FIGURE 12 VACCINES MARKET, BY DISEASE INDICATION, 2021 VS. 2026 (USD MILLION) 
    FIGURE 13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD MILLION) 
    FIGURE 14 VACCINES MARKET SHARE (EXCLUDING COVID-19 VACCINES), BY END USER, 2021 VS. 2026 
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET (EXCLUDING COVID-19 VACCINES)

4 PREMIUM INSIGHTS (Page No. - 60)
    4.1 VACCINES MARKET OVERVIEW (EXCLUDING COVID-19 VACCINES)
           FIGURE 16 GROWING PREVALENCE OF EMERGING AND RE-EMERGING INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY AND COUNTRY (2020)
           FIGURE 17 CONJUGATE VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN VACCINES MARKET IN 2020
    4.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 18 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE VACCINES MARKET FROM 2021 TO 2026

5 MARKET OVERVIEW (Page No. - 63)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 19 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing prevalence of emerging and re-emerging infectious diseases
                               TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
                    5.2.1.2 Increasing focus on immunization programs
                    5.2.1.3 Growing government support for vaccine development
                               TABLE 3 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION)
                    5.2.1.4 Increasing industry initiatives to enhance vaccine R&D
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of vaccine development
                    5.2.2.2 Low purchasing power in developing countries
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth prospects in emerging markets
                    5.2.3.2 Focus on therapeutic vaccines
                    5.2.3.3 Use of adjuvants in vaccines
           5.2.4 CHALLENGES
                    5.2.4.1 Inequitable access to vaccines
                               TABLE 4 IMMUNIZATION COVERAGE, BY DISEASE, 2020
    5.2.4.2 Vaccine misinformation
    5.3 IMPACT OF COVID-19 ON THE VACCINES MARKET
           TABLE 5 APPROVED COVID-19 VACCINES (NOVEMBER 2021)
           TABLE 6 COVID-19 VACCINES PIPELINE
           FIGURE 20 VACCINES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021 (USD BILLION)
    5.4 RANGES/SCENARIO
           FIGURE 21 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE VACCINES MARKET
    5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
           FIGURE 22 REVENUE SHIFT & NEW REVENUE POCKETS FOR VACCINE PROVIDERS
    5.6 PATENT ANALYSIS
           FIGURE 23 PATENTS GRANTED FOR VACCINES IN THE LAST 10 YEARS
           TABLE 7 INDICATIVE LIST OF PATENTS IN THE VACCINES MARKET
    5.7 PRICING ANALYSIS
           TABLE 8 MEDIAN PRICE PER DOSE OF SOME VACCINES (2020) (USD)
    5.8 VALUE CHAIN ANALYSIS
           FIGURE 24 VALUE CHAIN ANALYSIS OF THE VACCINES MARKET: R&D AND CLINICAL TRIAL PHASE CONTRIBUTES MAXIMUM VALUE
    5.9 ECOSYSTEM ANALYSIS
           FIGURE 25 ECOSYSTEM ANALYSIS: VACCINES MARKET
    5.10 REGULATORY LANDSCAPE
           FIGURE 26 REGULATORY APPROVAL PROCESS FOR VACCINES
           5.10.1 NORTH AMERICA
           5.10.2 EUROPE
                    TABLE 9 REGULATORY AUTHORITIES IN EUROPE
           5.10.3 ASIA PACIFIC
                    TABLE 10 REGULATORY AUTHORITIES IN ASIA PACIFIC
           5.10.4 REST OF THE WORLD
    5.11 PORTER’S FIVE FORCES ANALYSIS    

                       TABLE 11 VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF BUYERS
           5.11.4 BARGAINING POWER OF SUPPLIERS
           5.11.5 INTENSITY OF COMPETITIVE RIVALRY
    5.12 KEY PIPELINE PRODUCTS 

           TABLE 12 KEY PIPELINE VACCINES: GLAXOSMITHKLINE PLC (UK)
                    TABLE 13 KEY PIPELINE VACCINES: PFIZER, INC. (US)
                    TABLE 14 KEY PIPELINE VACCINES: MERCK & CO., INC. (US)
                   TABLE 15 KEY PIPELINE VACCINES: SANOFI S.A. (FRANCE)
    5.13 NEW VACCINE OPPORTUNITIES 
           5.13.1 HIV
                    5.13.1.1 HIV vaccines pipeline
                    5.13.1.2 HIV vaccines: Public-private initiatives and funding
           5.13.2 MALARIA
                    5.13.2.1 Malaria vaccines pipeline
                    5.13.2.2 Malaria vaccines: Public-private initiatives and funding
           5.13.3 ZIKA
                    5.13.3.1 Zika vaccines pipeline
                    5.13.3.2 Zika vaccines: Public-private initiatives and funding
           5.13.4 EBOLA
                    5.13.4.1 Ebola vaccines pipeline
                    5.13.4.2 Ebola vaccines: Public-private initiatives and funding
                    5.13.4.3 Ebola projects funded by EC (2014–2020)

6 VACCINES MARKET, BY TECHNOLOGY (Page No. - 93)
    6.1 INTRODUCTION
           TABLE 16 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
           TABLE 17 COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
    6.2 CONJUGATE VACCINES
           6.2.1 CONJUGATE VACCINES HOLD THE LARGEST SHARE OF THE MARKET
                    TABLE 18 COST OF PEDIATRIC MENINGOCOCCAL CONJUGATE VACCINES AVAILABLE IN THE US
                    TABLE 19 COST OF ADULT MENINGOCOCCAL CONJUGATE VACCINES AVAILABLE IN THE US
                    TABLE 20 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 21 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 22 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 23 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 24 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    6.3 RECOMBINANT VACCINES
           6.3.1 LACK OF POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES ARE DRIVING R&D ON RECOMBINANT VACCINES
                    TABLE 25 EXAMPLES OF RECOMBINANT VACCINES
                    TABLE 26 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 27 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 28 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 29 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 30 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    6.4 INACTIVATED & SUBUNIT VACCINES
           6.4.1 EASE OF STORAGE AND TRANSPORTATION HAVE MADE INACTIVATED & SUBUNIT VACCINES POPULAR
                    TABLE 31 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
                    TABLE 32 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 33 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 34 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 35 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 36 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    6.5 LIVE ATTENUATED VACCINES
           6.5.1 ISSUES IN PRESERVING AND MAINTAINING LIVE ATTENUATED VACCINES HAVE SLOWED MARKET GROWTH
                    TABLE 37 EXAMPLES OF LIVE ATTENUATED VACCINES
                    TABLE 38 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 39 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 40 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 41 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 42 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    6.6 TOXOID VACCINES
           6.6.1 COMPANY INITIATIVES AND THE INTRODUCTION OF NEW VACCINES WILL SUPPORT MARKET GROWTH
                    TABLE 43 EXAMPLES OF TOXOID VACCINES
                    TABLE 44 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 45 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 46 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 47 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 48 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    6.7 VIRAL VECTOR VACCINES
           6.7.1 VIRAL VECTOR VACCINES USE THE BODY’S OWN CELLS TO PRODUCE ANTIGENS
                    TABLE 49 EXAMPLES OF RECENTLY LAUNCHED VIRAL VECTOR VACCINES
                    TABLE 50 VIRAL VECTOR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)

7 VACCINES MARKET, BY TYPE (Page No. - 112)
    7.1 INTRODUCTION
           TABLE 51 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
           TABLE 52 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
    7.2 MONOVALENT VACCINES
           7.2.1 MONOVALENT VACCINES DOMINATE THE VACCINES MARKET
                    TABLE 53 EXAMPLES OF MONOVALENT VACCINES
                    TABLE 54 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 55 NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 56 EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 57 ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 58 LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 MULTIVALENT VACCINES
           7.3.1 INCREASING INITIATIVES BY COMPANIES TO DEVELOP NEW MULTIVALENT VACCINES TO DRIVE MARKET GROWTH
                    TABLE 59 EXAMPLES OF MULTIVALENT VACCINES
                    TABLE 60 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 61 NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 62 EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 63 ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 64 LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)

8 VACCINES MARKET, BY DISEASE INDICATION (Page No. - 120)
    8.1 INTRODUCTION
           TABLE 65 VACCINES MARKET, BY DISEASE INDICATION, 2019–2026 (USD MILLION)
    8.2 PNEUMOCOCCAL DISEASE
           8.2.1 PNEUMOCOCCAL DISEASE IS THE LARGEST DISEASE INDICATION SEGMENT OF THE MARKET
                    TABLE 66 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET
                    TABLE 67 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 68 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 69 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY BUYER, 2019–2026 (MILLION DOSES)
    8.3 INFLUENZA
           8.3.1 RISING DEMAND FOR INFLUENZA VACCINES FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET GROWTH
                    TABLE 70 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET
                    TABLE 71 INFLUENZA VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 72 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 COMBINATION VACCINES
           8.4.1 INCREASING DEMAND FOR ALL-IN-ONE VACCINES IS DRIVING THE GROWTH OF THIS SEGMENT
                    TABLE 73 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES IN THE MARKET
                    TABLE 74 COMBINATION VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 75 NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.5 HPV
           8.5.1 HPV VACCINES MARKET TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
                    TABLE 76 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
                    TABLE 77 HPV VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 78 NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 79 HPV VACCINES MARKET, BY BUYER, 2019–2026 (MILLION DOSES)
    8.6 MENINGOCOCCAL DISEASE
           8.6.1 RISING INCIDENCE OF MENINGOCOCCAL DISEASE TO SUPPORT THE GROWTH OF THIS SEGMENT
                    TABLE 80 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES IN THE MARKET
                    TABLE 81 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 82 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.7 HERPES ZOSTER
           8.7.1 HERPES ZOSTER VACCINES TO WITNESS STABLE DEMAND DURING THE FORECAST PERIOD
                    TABLE 83 HERPES ZOSTER VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 84 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.8 ROTAVIRUS
           8.8.1 RISING INCIDENCE OF ROTAVIRUS INFECTIONS TO DRIVE MARKET GROWTH
                    TABLE 85 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET
                    TABLE 86 ROTAVIRUS VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 87 NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 88 ROTAVIRUS VACCINES MARKET, BY BUYER, 2019–2026 (MILLION DOSES)
    8.9 MMR
           8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA IS SUPPORTING THE GROWTH OF THIS SEGMENT
                    TABLE 89 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET
                    TABLE 90 MMR VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 91 NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.10 VARICELLA
           8.10.1 PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE THE DEMAND FOR VARICELLA VACCINES
                    TABLE 92 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET
                    TABLE 93 VARICELLA VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 94 NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.11 HEPATITIS 
           8.11.1 HIGH PREVALENCE OF HEPATITIS INFECTIONS TO DRIVE THE DEMAND FOR IMMUNIZATION
                    TABLE 95 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET
                    TABLE 96 HEPATITIS VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 97 NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.12 DTP 
           8.12.1 INCREASING ACCESSIBILITY OF DTP VACCINES IN DEVELOPING COUNTRIES TO DRIVE MARKET GROWTH
                    TABLE 98 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET
                    TABLE 99 DTP VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 100 NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.13 POLIO 
           8.13.1 GOVERNMENT INITIATIVES TO SUPPORT THE GROWTH OF THIS SEGMENT
                    TABLE 101 POLIO VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 102 NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.14 COVID-19 
           8.14.1 EMERGENCE OF SARS-COV-2 VARIANTS COULD MAKE BOOSTER DOSES NECESSARY
                    TABLE 103 LIST OF WHO PREQUALIFIED COVID-19 VACCINES
                    TABLE 104 COVID-19 VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 105 NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 106 COVID-19 VACCINE DELIVERIES, BY COUNTRY (MILLION DOSES)
    8.15 OTHER DISEASE INDICATIONS

  TABLE 107 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
 TABLE 108 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 109 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)

9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 147)
    9.1 INTRODUCTION
           TABLE 110 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
           TABLE 111 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
    9.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
           9.2.1 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION ACCOUNTED FOR THE LARGEST MARKET SHARE
                    TABLE 112 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
                    TABLE 113 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 114 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 115 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 116 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 117 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 ORAL ADMINISTRATION
           9.3.1 POSSIBILITY OF IRRITATION OF THE GASTRIC MUCOSA IS LIMITING THE GROWTH OF THIS SEGMENT
                    TABLE 118 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                    TABLE 119 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 120 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 121 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 122 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 OTHER ROUTES OF ADMINISTRATION
           TABLE 123 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
           TABLE 124 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 125 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 126 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 127 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)

10 VACCINES MARKET, BY END USER (Page No. - 157)
     10.1 INTRODUCTION
               TABLE 128 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
     10.2 PEDIATRIC VACCINES
             10.2.1 PEDIATRIC VACCINES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
                       TABLE 129 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                       TABLE 130 NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 131 EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 132 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 133 LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
     10.3 ADULT VACCINES
             10.3.1 ADULT VACCINES SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
                       TABLE 134 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
                       TABLE 135 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 136 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 137 ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
                       TABLE 138 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)

11 VACCINES MARKET, BY REGION (Page No. - 164)
     11.1 INTRODUCTION
               FIGURE 27 VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES (EXCLUDING COVID-19 VACCINES)
               TABLE 139 VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
               TABLE 140 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
     11.2 NORTH AMERICA
               FIGURE 28 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
               TABLE 141 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 142 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
               TABLE 143 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 144 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
               TABLE 145 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
               TABLE 146 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.2.1 US
                       11.2.1.1 The US is the largest market for vaccines globally
                                   TABLE 147 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
                                   TABLE 148 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 149 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 150 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 151 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.2.2 CANADA
                       11.2.2.1 High incidence of infectious diseases is driving the demand for vaccines in the country
                                   TABLE 152 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
                                   TABLE 153 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 154 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 155 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 156 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
     11.3 EUROPE
               TABLE 157 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 158 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
               TABLE 159 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 160 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
               TABLE 161 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
               TABLE 162 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.1 GERMANY
                       11.3.1.1 Significant investments in R&D to support market growth
                                   TABLE 163 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 164 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 165 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 166 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.2 UK
                       11.3.2.1 Launch of new products and collaborations to support market growth in the UK in the coming years
                                   TABLE 167 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 168 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 169 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 170 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.3 FRANCE
                       11.3.3.1 Favorable government initiatives for immunization to support market growth in France
                                   TABLE 171 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 172 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 173 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 174 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.4 ITALY
                       11.3.4.1 Italy is the third-largest donor for the International Finance Facility for Immunization
                                   TABLE 175 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 176 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 177 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 178 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.5 SPAIN
                       11.3.5.1 Increasing investments in vaccine development by private organizations to support market growth in Spain
                                   TABLE 179 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 180 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 181 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 182 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.3.6 REST OF EUROPE
                       TABLE 183 ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 184 ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                       TABLE 185 ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                       TABLE 186 ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
     11.4 ASIA PACIFIC
               TABLE 187 ASIA PACIFIC: HEALTHCARE EXPENDITURE PER CAPITA, BY COUNTRY, 2017 VS. 2018 VS. 2019 (USD)
               FIGURE 29 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
               TABLE 188 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 189 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
               TABLE 190 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 191 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
               TABLE 192 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
               TABLE 193 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.4.1 CHINA
                       11.4.1.1 Growing investments in the biotechnology sector to drive market growth in China
                                   TABLE 194 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 195 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 196 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 197 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.4.2 JAPAN
                       11.4.2.1 Government initiatives for increasing the accessibility of vaccines to drive market growth in Japan
                                   TABLE 198 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 199 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 200 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 201 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.4.3 INDIA
                       11.4.3.1 Growth of the biotechnology sector and development of new vaccines to support market growth in India
                                   TABLE 202 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 203 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 204 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 205 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.4.4 SOUTH KOREA
                       11.4.4.1 Strong government boost to develop vaccine hubs in the country is expected to drive market growth
                                   TABLE 206 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 207 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 208 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 209 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.4.5 REST OF ASIA PACIFIC
                       TABLE 210 ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 211 ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                       TABLE 212 ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                       TABLE 213 ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
     11.5 LATIN AMERICA
               TABLE 214 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
               TABLE 215 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
               TABLE 216 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
               TABLE 217 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
               TABLE 218 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
               TABLE 219 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.5.1 BRAZIL
                       11.5.1.1 Rising focus on vaccination from governmental and non-governmental organizations to drive market growth
                                   TABLE 220 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                   TABLE 221 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                                   TABLE 222 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                                   TABLE 223 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
             11.5.2 REST OF LATIN AMERICA
                       TABLE 224 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 225 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                       TABLE 226 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                       TABLE 227 ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
     11.6 MIDDLE EAST AND AFRICA
             11.6.1 HIGH DEMAND FOR VACCINES DUE TO THE PREVALENCE OF INFECTIOUS DISEASES WILL DRIVE MARKET GROWTH
                       TABLE 228 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
                       TABLE 229 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
                       TABLE 230 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
                       TABLE 231 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
                       TABLE 232 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 213)
     12.1 OVERVIEW
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
               FIGURE 30 KEY PLAYER STRATEGIES IN THE VACCINES MARKET, 2018-2021
     12.3 MARKET SHARE ANALYSIS
               FIGURE 31 VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
     12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
               FIGURE 32 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE VACCINES MARKET, 2016–2020
     12.5 COMPANY EVALUATION QUADRANT
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                       FIGURE 33 VACCINES MARKET: COMPANY EVALUATION QUADRANT, 2020
     12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                       FIGURE 34 VACCINES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
     12.7 DISEASE INDICATION FOOTPRINT OF COMPANIES
               TABLE 233 DISEASE INDICATION PORTFOLIO ANALYSIS: VACCINES MARKET (2020)
     12.8 REGIONAL FOOTPRINT OF COMPANIES
               TABLE 234 REGIONAL FOOTPRINT ANALYSIS: VACCINES MARKET (2020)
     12.9 COMPETITIVE SCENARIO
             12.9.1 PRODUCT LAUNCHERS & APPROVALS
                       TABLE 235 VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–NOVEMBER 2021
             12.9.2 DEALS
                       TABLE 236 VACCINES MARKET: DEALS, JANUARY 2018–NOVEMBER 2021
             12.9.3 OTHER DEVELOPMENTS
                       TABLE 237 VACCINES MARKET: OTHER DEVELOPMENTS, JANUARY 2018–NOVEMBER 2021

13 COMPANY PROFILES (Page No. - 229)
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
     13.1 KEY COMPANIES
             13.1.1 GLAXOSMITHKLINE PLC
                       TABLE 238 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW
                       FIGURE 35 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2020)
             13.1.2 MERCK & CO., INC.
                       TABLE 239 MERCK & CO., INC.: BUSINESS OVERVIEW
                       FIGURE 36 MERCK & CO., INC.: COMPANY SNAPSHOT (2020)
             13.1.3 PFIZER, INC.
                       TABLE 240 PFIZER, INC.: BUSINESS OVERVIEW
                       FIGURE 37 PFIZER, INC.: COMPANY SNAPSHOT (2020)
             13.1.4 SANOFI SA
                       TABLE 241 SANOFI SA: BUSINESS OVERVIEW
                       FIGURE 38 SANOFI SA: COMPANY SNAPSHOT (2020)
             13.1.5 CSL LIMITED
                       TABLE 242 CSL LIMITED: BUSINESS OVERVIEW
                       FIGURE 39 CSL LIMITED: COMPANY SNAPSHOT (2020)
             13.1.6 EMERGENT BIOSOLUTIONS, INC.
                       TABLE 243 EMERGENT BIOSOLUTIONS, INC.: BUSINESS OVERVIEW
                       FIGURE 40 MERGENT BIOSOLUTIONS, INC.: COMPANY SNAPSHOT (2020)
             13.1.7 JOHNSON & JOHNSON
                       TABLE 244 JOHNSON & JOHNSON: BUSINESS OVERVIEW
                       FIGURE 41 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020)
             13.1.8 ASTRAZENECA PLC
                       TABLE 245 ASTRAZENECA PLC: BUSINESS OVERVIEW
                       FIGURE 42 ASTRAZENECA PLC: COMPANY SNAPSHOT (2020)
             13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD.
                       TABLE 246 SERUM INSTITUTE OF INDIA PVT. LTD.: BUSINESS OVERVIEW
             13.1.10 BAVARIAN NORDIC A/S
                       TABLE 247 BAVARIAN NORDIC A/S: BUSINESS OVERVIEW
                       FIGURE 43 BAVARIAN NORDIC A/S: COMPANY SNAPSHOT (2020)
             13.1.11 MITSUBISHI TANABE PHARMA CORPORATION
                       TABLE 248 MITSUBISHI TANABE PHARMA CORPORATION: BUSINESS OVERVIEW
             13.1.12 DAIICHI SANKYO COMPANY, LIMITED
                       TABLE 249 DAIICHI SANKYO COMPANY, LIMITED: BUSINESS OVERVIEW
                       FIGURE 44 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2020)
             13.1.13 PANACEA BIOTEC
                       TABLE 250 PANACEA BIOTEC: BUSINESS OVERVIEW
                       FIGURE 45 PANACEA BIOTEC: COMPANY SNAPSHOT (2020)
             13.1.14 BIOLOGICAL E LIMITED
                       TABLE 251 BIOLOGICAL E LIMITED: BUSINESS OVERVIEW
             13.1.15 BHARAT BIOTECH
                       TABLE 252 BHARAT BIOTECH: BUSINESS OVERVIEW
             13.1.16 NOVAVAX, INC.
                       TABLE 253 NOVAVAX, INC.: BUSINESS OVERVIEW
                       FIGURE 46 NOVAVAX, INC.: COMPANY SNAPSHOT (2020)
             13.1.17 FSUE NPO MICROGEN
                       TABLE 254 FSUE NPO MICROGEN: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     13.2 OTHER COMPANIES
             13.2.1 SINOVAC BIOTECH LTD.
             13.2.2 INCEPTA VACCINE LTD.
             13.2.3 VALNEVA SE
             13.2.4 VBI VACCINES INC.
             13.2.5 PT BIO FARMA (PERSERO)
             13.2.6 INOVIO PHARMACEUTICALS, INC.
             13.2.7 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
             13.2.8 INDIAN IMMUNOLOGICALS LIMITED

14 APPENDIX (Page No. - 294)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global vaccines market. Interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The vaccine market size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the World Health Organization, Organisation for Economic Co-operation and Development, World Bank, Centers for Disease Control and Prevention, American Cancer Society, US Food and Drug Administration, European Commission, European Centre for Disease Prevention and Control, National Institutes of Health, National Institute of Allergy and Infectious Diseases, United Nations’ Children Fund, Gavi - The Vaccine Alliance, Pan American Health Organization, Biomedical Advanced Research & Development Authority, Program for Appropriate Technology in Health (PATH), Coalition for Epidemic Preparedness Innovations (CEPI), and International AIDS Vaccine Initiative (IAVI). Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations, among others. Secondary data was collected and analyzed to arrive at the overall size of the global vaccines market, which was validated through primary research.

Primary Research

After acquiring basic knowledge about the global vaccines market scenario through secondary research, extensive primary research was conducted after acquiring basic knowledge about the global vaccines market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the purchase & sales department, research organizations, and doctors) and supply side (such as C-level and D-level executives, product managers, manufacturing managers, marketing & sales managers of key manufacturers, distributors, and channel partners, among others) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Vaccines Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the vaccines market was estimated through different approaches. A detailed market estimation approach was followed to estimate and validate the global market value and other dependent submarkets, as mentioned below. Both top-down and bottom-up approaches were used to estimate and validate the total size of the vaccines market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the vaccines business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global vaccines market on the basis of technology, type, disease indication, route of administration, end user, and region
  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall vaccines market
  • To analyze the market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East and Africa (MEA)
  • To profile the key players and comprehensively analyze their product portfolios, market shares and rankings, and core competencies
  • To track and analyze competitive developments, such as acquisitions, product launches, expansions, regulatory approvals, agreements, partnerships, and collaborations in the global vaccines market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the European vaccines market into countries from the Rest of Europe.
  • Further breakdown of the Asia Pacific vaccines market into countries from the Rest of the APAC.
  • Further breakdown of the Latin America vaccines market into Brazil, Mexico, and the Rest of Latin America.

Company Information

Detailed analysis and profiling of additional market players (up to 5), inclusive of:

  • Business Overview
  • Financial Information
  • Product Portfolio
  • Developments (Last Three Years)
Report Code
PH 6528
Published ON
Jan, 2022
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Vaccines Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved